Latest news

• GSK’s Jemperli made available to endometrial cancer patients via UK’s early access scheme

  GSK has announced that eligible endometrial cancer patients in the UK will be granted early access to its anti-PD-1 therapy Jemperli (dostarlimab) in combination with platinum-containing chemotherapy via

• GSK’s Jemperli shows promise in phase 3 endometrial cancer trial

  GSK has announced positive results from a planned interim analysis of part one of its phase 3 RUBY trial, investigating Jemperli (dostarlimab) in the treatment of adult patients with primary advanced

• FDA approval for Roche diagnostic solid tumour test

  identify patients whose solid tumours are deficient in DNA mismatch repair (MMR) and who may benefit from GSK’s anti-PD-1 immunotherapy treatment Jemperli (dostarlimab-gxly).

• GSK partners with iTeos Therapeutics on next-gen immuno-oncology drug

  GSK and iTeos are also planning to launch combination studies of the mAb with PD-1 inhibitor Jemperli (dostarlimab) in 2022.

• GSK wins approval for anti-PD-1 antibody Jemperli in endometrial cancer

  The Food and Drug Administration (FDA) has approved Jemperli(dostarlimab-gxly) for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, following an FDA-approved